Sponsor or institution
Clinical trials and research at Deciphera Pharmaceuticals, LLC
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Deciphera Pharmaceuticals, LLC that are recruiting, in United States. By phase: Phase 1 (2), Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Vimseltinib’s effect on P-glycoprotein inhibition in healthy men | Phase 1 | Overland Park, Kansas | Recruiting | Aug 4, 2026 |
| Real-world experience with vimseltinib for tenosynovial giant cell tumor | — | Wilmington, North Carolina | Recruiting | Jul 20, 2025 |
| DCC-2812 in advanced kidney, bladder, and castration-resistant prostate cancers | Phase 1 | Boston, Massachusetts and 7 other locations | Recruiting | May 11, 2025 |
| Evaluating DCC-3009 for treating gastrointestinal stromal tumors | Phase 1/2 | Scottsdate, Arizona and 9 other locations | Recruiting | Oct 8, 2024 |
| Evaluating Vimseltinib for Chronic Graft-Versus-Host Disease in Adults | Phase 2 | Duarte, California and 25 other locations | Recruiting | Oct 1, 2024 |
All recruiting trials (5)
-
Vimseltinib’s effect on P-glycoprotein inhibition in healthy men
This study tests whether vimseltinib changes how a P-glycoprotein substrate (dabigatran) behaves in the body of healthy men.
-
Real-world experience with vimseltinib for tenosynovial giant cell tumor
This registry will collect real-world information about how people with TGCT take vimseltinib and how it affects their symptoms and quality of life.
-
DCC-2812 in advanced kidney, bladder, and castration-resistant prostate cancers
This trial will test whether the oral drug DCC-2812 is safe and shows early signs of benefit for people with advanced kidney (renal cell), bladder (urothelial), or castration-resistant prostate cancer.
-
Evaluating DCC-3009 for treating gastrointestinal stromal tumors
This study is testing a new treatment called DCC-3009 for people with gastrointestinal stromal tumors to see if it is safe and effective, either on its own or with other cancer therapies.
-
Evaluating Vimseltinib for Chronic Graft-Versus-Host Disease in Adults
This study is testing if a new medication called vimseltinib can help adults with tough cases of chronic graft-versus-host disease feel better after other treatments haven't worked.
Quick answers
How many clinical trials run by Deciphera Pharmaceuticals, LLC are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.